Another USP10 inhibitor, Wu-5, also shows anti-AML effect and overcomes FLT3 inhibitor resistance and synergistically enhances the anti-leukemia effect of crenolanib through targeting both FLT3 and AMPKα pathway [74]. This evidence concerns the gene FLT3 and leukemia.